L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease

Lipids in Health and Disease

Oren Tirosh¹  Sarit Anavi¹  Michal Hahn-Obercyger¹  Irina Voloshin¹ 

[1] Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel

关键词: Metabolic syndrome;    Obesity;    Over-nutrition;    Steatosis;    Liver damage;   

Others  :  805055
DOI  :  10.1186/1476-511X-13-69

 received in 2014-02-10, accepted in 2014-04-09,  发布年份 2014

【 摘 要 】

Background

Non-alcoholic fatty liver disease (NAFLD) is a continuum of diseases that include simple steatosis and non-alcoholic steatohepatitis (NASH) ultimately leading to cirrhosis, hepatocellular carcinoma and end stage liver failure. Currently there is no approved treatment for NASH. It is known that bile acids not only have physiological roles in lipid digestion but also have strong hormonal properties. We have synthesized a novel chenodeoxycholyl-arginine ethyl ester conjugate (CDCArg) for the treatment of NAFLD.

Methods

Chemical synthesis of CDCArg was performed. Experiments for prevention and treatment of NAFLD were carried out on C57BL/6 J male mice that were treated with high fat diet (HFD, 60% calories from fat). CDCArg or cholic acid bile acids were admixture into the diets. Food consumption, weight gain, liver histology, intraperitoneal glucose tolerance test, biochemical analysis and blood parameters were assessed at the end of the experiment after 5 weeks of diet (prevention study) or after 14 weeks of diet (treatment study). In the treatment study CDCArg was admixture into the diet at weeks 10–14.

Results

In comparison to HFD treated mice, mice treated with HFD supplemented with CDCArg, showed reduced liver steatosis, reduced body weight and decreased testicular fat and liver tissue mass. Blood glucose, cholesterol, insulin and leptin levels were also lower in this group. No evidence of toxicity of CDCArg was recorded. In fact, liver injury, as evaluated using plasma hepatic enzyme levels, was low in mice treated with HFD and CDCArg when compared to mice treated with HFD and cholic acid.

Conclusion

CDCArg supplementation protected the liver against HFD-induced NAFLD without any toxic effects. These results indicate that basic amino acids e.g., L-arginine and bile acids conjugates may be a potential therapy for NAFLD.

【 授权许可】

   
2014 Voloshin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F: Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med 2013, 19:522-535.
• [2]Musso G, Gambino R, Cassader M: Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010, 61:375-392.
• [3]Musso G, Gambino R, Cassader M: Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010, 11:430-445.
• [4]Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007, 47:239-244.
• [5]Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP: Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000, 69:2410-2415.
• [6]Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
• [7]Moore JB: Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010, 69:211-220.
• [8]Alwahsh SM, Xu M, Seyhan HA, Ahmad S, Mihm S, Ramadori G, Schultze FC: Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J Gastroenterol 2014, 20:1807-1821.
• [9]Fujii H, Kawada N: Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 2012, 47:215-225.
• [10]Karpen SJ: Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? Gastroenterology 2013, 145:508-510.
• [11]Li Y, Jadhav K, Zhang Y: Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013, 86:1517-1524.
• [12]Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S: Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-1403.
• [13]Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, Rodrigues CM: Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008, 20:519-525.
• [14]Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A: Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013, 57:1394-1406.
• [15]Myher JJ, Marai L, Kuksis A, Yousef IM, Fisher MM: Identification of ornithine and arginine conjugates of cholic acid by mass spectrometry. Can J Biochem 1975, 53:583-590.
• [16]Song P, Zhang Y, Klaassen CD: Dose–response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol Sci 2011, 123:359-367.
• [17]Chiang JY: Bile acid metabolism and signaling. Compr Physiol 2013, 3:1191-1212.
• [18]Haedrich M, Dufour JF: UDCA for NASH: end of the story? J Hepatol 2011, 54:856-858.
• [19]Sievanen E: Exploitation of bile acid transport systems in prodrug design. Molecules 2007, 12:1859-1889.
• [20]Stepanov V, Stankov K, Mikov M: The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 2013, 33:213-223.
• [21]Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, Schoonjans K: TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012, 2:430.
• [22]Steinert RE, Peterli R, Keller S, Meyer-Gerspach AC, Drewe J, Peters T, Beglinger C: Bile acids and gut peptide secretion after bariatric surgery: A 1-year prospective randomized pilot trial. Obesity (Silver Spring) 2013, 21(12):E660-E668.
• [23]Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB: Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487:104-108.
• [24]Canale MP, Manca di Villahermosa S, Martino G, Rovella V, Noce A, De Lorenzo A, Di Daniele N: Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol 2013, 2013:865965.
• [25]Mark AL: Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol 2013, 305:R566-R581.
• [26]Yamagata K, Yoshimochi K, Daitoku H, Hirota K, Fukamizu A: Bile acid represses the peroxisome proliferator-activated receptor-gamma coactivator-1 promoter activity in a small heterodimer partner-dependent manner. Int J Mol Med 2007, 19:751-756.
• [27]Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, Fuchs M, Sargeant C, Warnick GR, Siddiqui MS1, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, Fuchs M, Sargeant C, Warnick GR, Grami S, Sanyal AJ: Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013, 145:1271-1279. e1271-1273
• [28]Farrell GC, van Rooyen D: Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol 2012, 303(1):G9-G11.
• [29]Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
• [30]Anavi S, Harmelin NB, Madar Z, Tirosh O: Oxidative stress impairs HIF1alpha activation: a novel mechanism for increased vulnerability of steatotic hepatocytes to hypoxic stress. Free Radic Biol Med 2012, 52:1531-1542.
• [31]Budick-Harmelin N, Anavi S, Madar Z, Tirosh O: Fatty acids-stress attenuates gluconeogenesis induction and glucose production in primary hepatocytes. Lipids Health Dis 2012, 11:66. BioMed Central Full Text